Bioequivalence Study of UHAC62XX Tablets Compared With Capsules in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: UHAC 62 XX capsuleDrug: UHAC 62 XX tablet
- First Posted Date
- 2014-07-11
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 26
- Registration Number
- NCT02187575
BIBR 277 Capsules in Hypertensive Patients With Nephropathy
- First Posted Date
- 2014-07-11
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 23
- Registration Number
- NCT02187484
Pharmacokinetics of BIBR 277 in Hypertensive Patients
Phase 2
Completed
- Conditions
- Hypertension
- Interventions
- Drug: Medium dose of BIBR 277Drug: Low dose of BIBR 277Drug: High dose of BIBR 277
- First Posted Date
- 2014-07-11
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 93
- Registration Number
- NCT02187497
Effect of Steady State Meloxicam on Low Dose Aspirin Induced Inhibition of Platelet Aggregation and Thromboxane Synthesis in Healthy Males and Females
- First Posted Date
- 2014-07-11
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT02187562
Pharmacokinetic Properties of Two Dosages Nevirapine Extended Release (XR) Formulations Compared to VIRAMUNE® Tablet as Well as to Nevirapine XR Tablet in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 96
- Registration Number
- NCT02184312
Efficacy and Safety of Metamizole Versus Placebo as Antithermic Therapy in the Acute Phase of Ischemic Stroke
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2014-07-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 58
- Registration Number
- NCT02184260
Efficacy and Safety of Meloxicam (Mobicox®) in Mexican Population With Rheumatic Diseases
Completed
- Conditions
- Osteoarthritis
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2014-07-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12687
- Registration Number
- NCT02184039
Safety and Tolerability of Kiddi® Pharmaton Fizz Effervescent Tablets in Children
Phase 2
Completed
- Conditions
- Healthy
- Interventions
- Drug: Kiddi® Pharmaton Fizz, effervescent tabletsDrug: Comparator product
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 96
- Registration Number
- NCT02184325
Study to Evaluate the Effects of Underlying Renal or Hepatic Dysfunction on the Pharmacokinetics of Nevirapine
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 41
- Registration Number
- NCT02184091
Pharmacokinetic Interaction Between Nevirapine and Saquinavir-sgc in HIV-1 Infected Patients
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 5
- Registration Number
- NCT02184286